216 related articles for article (PubMed ID: 31047503)
1. Ranibizumab Induces Regression of Diabetic Retinopathy in Most Patients at High Risk of Progression to Proliferative Diabetic Retinopathy.
Wykoff CC; Eichenbaum DA; Roth DB; Hill L; Fung AE; Haskova Z
Ophthalmol Retina; 2018 Oct; 2(10):997-1009. PubMed ID: 31047503
[TBL] [Abstract][Full Text] [Related]
2. Long-term Effects of Intravitreal 0.19 mg Fluocinolone Acetonide Implant on Progression and Regression of Diabetic Retinopathy.
Wykoff CC; Chakravarthy U; Campochiaro PA; Bailey C; Green K; Cunha-Vaz J
Ophthalmology; 2017 Apr; 124(4):440-449. PubMed ID: 28081945
[TBL] [Abstract][Full Text] [Related]
3. Baseline Diabetic Retinopathy Severity and Time to Diabetic Macular Edema Resolution with Ranibizumab Treatment: A Meta-Analysis.
Talcott KE; Valentim CCS; Hill L; Stoilov I; Singh RP
Ophthalmol Retina; 2023 Jul; 7(7):605-611. PubMed ID: 36774994
[TBL] [Abstract][Full Text] [Related]
4. Panretinal Photocoagulation for Diabetic Retinopathy in the RIDE and RISE Trials: Not "1 and Done".
Gonzalez VH; Wang PW; Ruiz CQ
Ophthalmology; 2021 Oct; 128(10):1448-1457. PubMed ID: 31668888
[TBL] [Abstract][Full Text] [Related]
5. Predictors of Early Diabetic Retinopathy Regression with Ranibizumab in the RIDE and RISE Clinical Trials.
Singer M; Liu M; Schlottmann PG; Khanani AM; Hemphill M; Hill L; Tuomi L; Haskova Z
Clin Ophthalmol; 2020; 14():1629-1639. PubMed ID: 32606578
[TBL] [Abstract][Full Text] [Related]
6. Effect of less aggressive treatment on diabetic retinopathy severity scale scores: analyses of the RIDE and RISE open-label extension.
Goldberg RA; Hill L; Davis T; Stoilov I
BMJ Open Ophthalmol; 2022 Jul; 7(1):. PubMed ID: 36161830
[TBL] [Abstract][Full Text] [Related]
7. The Clinical Importance of Changes in Diabetic Retinopathy Severity Score.
Ip MS; Zhang J; Ehrlich JS
Ophthalmology; 2017 May; 124(5):596-603. PubMed ID: 28284785
[TBL] [Abstract][Full Text] [Related]
8. Ultra-Response to Ranibizumab: Improvement by 4 or More Steps in Diabetic Retinopathy Severity in Diabetic Retinopathy Clinical Research Network Protocol S.
Chiang A; Garg SJ; Klufas MA; Ho AC; Hill L; Tsuboi M; Stoilov I
Ophthalmol Retina; 2021 Mar; 5(3):251-260. PubMed ID: 32735903
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Ranibizumab in Eyes with Diabetic Macular Edema and Macular Nonperfusion in RIDE and RISE.
Reddy RK; Pieramici DJ; Gune S; Ghanekar A; Lu N; Quezada-Ruiz C; Baumal CR
Ophthalmology; 2018 Oct; 125(10):1568-1574. PubMed ID: 29752001
[TBL] [Abstract][Full Text] [Related]
10. Visual and Anatomic Outcomes in Patients with Diabetic Macular Edema with Limited Initial Anatomic Response to Ranibizumab in RIDE and RISE.
Pieramici DJ; Wang PW; Ding B; Gune S
Ophthalmology; 2016 Jun; 123(6):1345-50. PubMed ID: 26992841
[TBL] [Abstract][Full Text] [Related]
11. Durability of Diabetic Retinopathy Improvement with As-Needed Ranibizumab: Open-Label Extension of RIDE and RISE Studies.
Sun JK; Wang PW; Taylor S; Haskova Z
Ophthalmology; 2019 May; 126(5):712-720. PubMed ID: 30419298
[TBL] [Abstract][Full Text] [Related]
12. Long-term effects of ranibizumab on diabetic retinopathy severity and progression.
Ip MS; Domalpally A; Hopkins JJ; Wong P; Ehrlich JS
Arch Ophthalmol; 2012 Sep; 130(9):1145-52. PubMed ID: 22965590
[TBL] [Abstract][Full Text] [Related]
13. Vision-related function after ranibizumab treatment for diabetic macular edema: results from RIDE and RISE.
Bressler NM; Varma R; Suñer IJ; Dolan CM; Ward J; Ehrlich JS; Colman S; Turpcu A;
Ophthalmology; 2014 Dec; 121(12):2461-72. PubMed ID: 25148789
[TBL] [Abstract][Full Text] [Related]
14. Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab.
Bressler SB; Liu D; Glassman AR; Blodi BA; Castellarin AA; Jampol LM; Kaufman PL; Melia M; Singh H; Wells JA;
JAMA Ophthalmol; 2017 Jun; 135(6):558-568. PubMed ID: 28448655
[TBL] [Abstract][Full Text] [Related]
15. Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy.
Ip MS; Domalpally A; Sun JK; Ehrlich JS
Ophthalmology; 2015 Feb; 122(2):367-74. PubMed ID: 25439595
[TBL] [Abstract][Full Text] [Related]
16. Evaluating the Impact of Intravitreal Aflibercept on Diabetic Retinopathy Progression in the VIVID-DME and VISTA-DME Studies.
Mitchell P; McAllister I; Larsen M; Staurenghi G; Korobelnik JF; Boyer DS; Do DV; Brown DM; Katz TA; Berliner A; Vitti R; Zeitz O; Metzig C; Lu C; Holz FG
Ophthalmol Retina; 2018 Oct; 2(10):988-996. PubMed ID: 31047501
[TBL] [Abstract][Full Text] [Related]
17. Association of Predominantly Peripheral Lesions on Ultra-Widefield Imaging and the Risk of Diabetic Retinopathy Worsening Over Time.
Marcus DM; Silva PS; Liu D; Aiello LP; Antoszyk A; Elman M; Friedman S; Glassman AR; Googe JM; Jampol LM; Martin DF; Melia M; Preston CM; Wykoff CC; Sun JK;
JAMA Ophthalmol; 2022 Oct; 140(10):946-954. PubMed ID: 35980608
[TBL] [Abstract][Full Text] [Related]
18. Update on Management of Non-proliferative Diabetic Retinopathy without Diabetic Macular Edema; Is There a Paradigm Shift?
Arabi A; Tadayoni R; Ahmadieh H; Shahraki T; Nikkhah H
J Ophthalmic Vis Res; 2022; 17(1):108-117. PubMed ID: 35194501
[TBL] [Abstract][Full Text] [Related]
19. Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
; Gross JG; Glassman AR; Jampol LM; Inusah S; Aiello LP; Antoszyk AN; Baker CW; Berger BB; Bressler NM; Browning D; Elman MJ; Ferris FL; Friedman SM; Marcus DM; Melia M; Stockdale CR; Sun JK; Beck RW
JAMA; 2015 Nov; 314(20):2137-2146. PubMed ID: 26565927
[TBL] [Abstract][Full Text] [Related]
20. Diabetic Population-Based Model to Estimate Impact of Ranibizumab on Diabetic Retinopathy Severity in Patients with Diabetic Macular Edema.
Varma R; Bressler NM; Doan QV; Suñer IJ; Danese M; Dolan CM; Lee A; Ehrlich JS; Rajput Y
Clin Ophthalmol; 2020; 14():1249-1259. PubMed ID: 32440092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
